This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Surgical and Transcatheter Management of MR: Competing or Complementary?

Thursday, May 21, 2020

Kaneko T, Tang GHL, Ailawadi G, Reardon MJ. Surgical and Transcatheter Management of MR: Competing or Complementary?. May 2020. doi:10.25373/ctsnet.12320843

Filmed at the 2020 STS Annual Meeting in New Orleans, Louisiana, Tsuyoshi Kaneko of Brigham and Women's Hospital in Boston, Massachusetts, USA, moderates a discussion on surgical and transcatheter management of mitral regurgitation (MR). He is joined by Michael J. Reardon of Houston Methodist Hospital in Texas, USA, Gorav Ailawadi of the University of Virginia, and Gilbert H. L. Tang of Mount Sinai Health System in New York City. They discuss the use of transcatheter vs. surgical therapies to treat MR.They focus both on degenerative and funtional MR, patient selection, and the the future of this field.


Dr Kaneko has a relationship with Medtronic, Edwards Lifesciences, Abbott, and Baylis Medical.

Dr Tang is a physician proctor for Edwards Lifesciences and Medtronic, as well as a consultant for Abbott, W. L. Gore & Associates, and Medtronic.

Dr Reardon is a consultant for Medtronic, Roston Scientific, and Gove Medical.


The information and views presented on represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Add comment

Log in or register to post comments